Resource impact statement

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the guidance covers a small population of around 300 people.

The guidance requires FLT3 gene mutation analysis earlier after the initial diagnostic blood and bone marrow sampling than is current practice (within 7 days instead of 2 to 4 weeks), which may increase costs. But even if the cost doubled to £300 per test, the total would still be below £5 million per year in England.

The list price of midostaurin has a discount that is commercial in confidence. For enquiries about the patient access scheme contact

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 13 June 2018